Nanosphere's Q4 Revenues Rise 35 Percent; Firm Gets FDA Warning Letter | GenomeWeb

NEW YORK (GenomeWeb) – Nanosphere reported after the close of the market Wednesday preliminary fourth quarter revenue growth of 35 percent year over year.

The Northbrook, Ill.-based molecular diagnostics firm also said that it has received a warning letter from the US Food and Drug Administration related to deficiencies in the firm's quality system regulation.

For the quarter ended Dec. 31, Nanosphere reported preliminary revenues of $4.6 million, up from $3.4 million in the fourth quarter of 2014. Analysts, on average, expected revenues of $4.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.